Literature DB >> 32335060

Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer.

Karl H Tully1, Florian Roghmann2, Joachim Noldus2, Xi Chen3, Lorine Häuser1, Adam S Kibel3, Guru P Sonpavde4, Matthew Mossanen3, Quoc-Dien Trinh5.   

Abstract

INTRODUCTION: The objective of this study was to examine the overall survival (OS) in patients diagnosed with high-grade T1 non-muscle-invasive bladder cancer treated with early radical cystectomy versus local treatment of the primary tumor, defined as endoscopic management with or without intravesical chemotherapy or immunotherapy. PATIENTS AND METHODS: We identified 4900 patients with histologically confirmed, clinically non-metastatic high-grade T1 bladder cancer undergoing surgical intervention using the National Cancer Database for the period 2010 to 2015. Multivariable logistic regression was used to examine predictors for the receipt of early radical cystectomy (defined as radical cystectomy within 90 days of diagnosis). We then employed multivariable Cox proportional hazards regression models and Kaplan-Meier curves to evaluate the OS according to surgical treatment (early radical cystectomy vs. local treatment).
RESULTS: A minority (23.7%) of patients underwent early radical cystectomy. Independent predictors of undergoing early radical cystectomy included lower age, White race, and lower comorbidity status. The median OS was 74.0 months for patients diagnosed with high-grade T1 bladder cancer. The 1- and 5-year survival rates of patients undergoing early radical cystectomy were 94.8% and 71.0%, whereas they were 85.2% and 52.4%, for patients undergoing initial local treatment, respectively (P < .001). Compared with patients undergoing local treatment, patients undergoing early radical cystectomy had a lower risk of all-cause mortality (hazard ratio, 0.78; 95% confidence interval, 0.67-0.91; P = .002).
CONCLUSION: In this cohort of patients presenting with high-grade T1 non-muscle-invasive bladder cancer, we found that early radical cystectomy was associated with an OS benefit compared with initial local treatment.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder cancer; NMIBC; Pelvic lymph node dissection; Radical Cystectomy; Transurethral resection

Year:  2020        PMID: 32335060     DOI: 10.1016/j.clgc.2020.03.013

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  3 in total

Review 1.  Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage.

Authors:  Adithya Balasubramanian; Ashray Gunjur; Andrew Weickhardt; Nathan Papa; Damien Bolton; Nathan Lawrentschuk; Marlon Perera
Journal:  World J Urol       Date:  2022-01-27       Impact factor: 4.226

2.  Effectiveness of Early Radical Cystectomy for High-Risk Non-Muscle Invasive Bladder Cancer.

Authors:  Elliott Diamant; Mathieu Roumiguié; Alexandre Ingels; Jérôme Parra; Dimitri Vordos; Anne-Sophie Bajeot; Emmanuel Chartier-Kastler; Michel Soulié; Alexandre de la Taille; Morgan Rouprêt; Thomas Seisen
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

Review 3.  Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR).

Authors:  Mihaela Georgiana Musat; Christina Soeun Kwon; Elizabeth Masters; Slaven Sikirica; Debduth B Pijush; Anna Forsythe
Journal:  Clinicoecon Outcomes Res       Date:  2022-01-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.